Free tool
FAERS Monitor: Protopam Chloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018799 or its brand name (Protopam Chloride, Pralidoxime Chloride). Reports on generic versions are filed under their own applications.
Reports
26
Serious
15
58% of reports
Hospitalization
10
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- accidental exposure6
- expired drug administered5
- injection site injury4
- drug ineffective3
- accidental exposure to product2
- expired product administered2
- extrapyramidal disorder2
- injection site pain2
- mental disorder due to a general medical condition2
- peripheral swelling2
- agitation1
- agranulocytosis1
- apnoea1
- asthma1
- basal ganglia haemorrhage1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2024 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,133 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mental disorder due to a general medical condition | 2 | 5207.6 | 1368.8 | 5,818 |
| accidental exposureSignal | 6 | 1167.4 | 578.3 | 5,867 |
| basal ganglia haemorrhage | 1 | 996.0 | 145.6 | 248 |
| expired drug administeredSignal | 5 | 818.1 | 371.9 | 3,302 |
| injection site injurySignal | 4 | 584.0 | 237.0 | 1,781 |
| apnoea | 1 | 103.9 | 15.2 | 25 |
| extrapyramidal disorder | 2 | 65.2 | 17.2 | 70 |
| expired product administered | 2 | 48.7 | 12.9 | 52 |
| agranulocytosis | 1 | 43.5 | 6.4 | 10 |
| accidental exposure to product | 2 | 15.7 | 4.1 | 15 |
| agitation | 1 | 11.0 | 1.6 | 2 |
| peripheral swelling | 2 | 10.5 | 2.8 | 9 |
| asthma | 1 | 7.2 | 1.0 | 1 |
| injection site pain | 2 | 5.3 | 1.4 | 3 |
| drug ineffective | 3 | 1.8 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.